Skip to content
value.today

ADARx Pharmaceuticals, Inc.

🇺🇸 San Diego, California, USAPharmaceuticalsFounded 2019
Total raised
$353 M
7 rounds on record
Latest round
$200 M
Aug 2023
First round on record
Jan 2020
Today
Private
No later event on record

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of ADARx Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2023$200 MNo. 7$50 to $250 million

ADARx Pharmaceuticals, Inc.: Raise no. 7, Aug 2023

Investors in this round

28 investors had bought by the notice of Aug 10, 2023: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for ADARx Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$200 M of $200 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Rui Zhu · Executive Officer
  • Zhen Li · Executive Officer, Director, Promoter
  • Carl Gordon · Director
  • Chen Yu · Director
  • Erez Chimovits · Director
  • Judith Li · Director
  • Lorence Kim · Director
  • Ricky Sun · Director
  • Sheila Gujrathi · Director
  • Simeon George · Director
  • Yuan (Eliza) Sun · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Zhen Li, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 10, 2023. Read the notice at the SEC.

equitySEC
Jan 2023$46 MNo. 6$10 to $50 million

ADARx Pharmaceuticals, Inc.: Raise no. 6, Jan 2023

Investors in this round

10 investors had bought by the notice of Jan 26, 2023: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for ADARx Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$46 M of $46 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Rui Zhu · Executive Officer
  • Zhen Li · Executive Officer, Director
  • Carl Gordon · Director
  • Erez Chimovits · Director
  • Judith Li · Director
  • Lorence Kim · Director
  • Sheila Gujrathi · Director
  • Simeon George · Director
  • Yuan (Eliza) Sun · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Zhen Li, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 26, 2023. Read the notice at the SEC.

equitySEC
Jul 2021$75 MNo. 5$50 to $250 million

ADARx Pharmaceuticals, Inc.: Raise no. 5, Jul 2021

Investors in this round

6 investors had bought by the notice of Aug 17, 2021: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for ADARx Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$75 M of $75 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Rui Zhu · Executive Officer
  • Zhen Li · Executive Officer, Director
  • Carl Gordon · Director
  • Erez Chimovits · Director
  • Sheila Gujrathi · Director
  • Simeon George · Director
  • Xiong Zhang · Director
  • Yuan Sun · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Zhen Li, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 17, 2021. Read the notice at the SEC.

equitySEC
May 2021$16 MNo. 4$10 to $50 million

ADARx Pharmaceuticals, Inc.: Raise no. 4, May 2021

Investors in this round

3 investors had bought by the notice of May 24, 2021: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for ADARx Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$16 M of $16 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Rui Zhu · Executive Officer
  • Zhen Li · Executive Officer, Director
  • Carl Gordon · Director
  • Erez Chimovits · Director
  • Sheila Gujrathi · Director
  • Xiong Zhang · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Zhen Li, President & CEO. Source: SEC Form D, newest notice filed May 24, 2021. Read the notice at the SEC.

equitySEC
Nov 2020$6 MNo. 3$2 to $10 million

ADARx Pharmaceuticals, Inc.: Raise no. 3, Nov 2020

Investors in this round

3 investors had bought by the notice of Nov 17, 2020: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for ADARx Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Rui Zhu · Executive Officer
  • Zhen Li · Executive Officer, Director
  • Carl Gordon · Director
  • Erez Chimovits · Director
  • Hongbo Lu · Director
  • Sheila Gujrathi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Zhen Li, President & CEO. Source: SEC Form D, newest notice filed Nov 17, 2020. Read the notice at the SEC.

equitySEC
Jul 2020$5 MNo. 2$2 to $10 million

ADARx Pharmaceuticals, Inc.: Raise no. 2, Jul 2020

Investors in this round

3 investors had bought by the notice of Aug 7, 2020: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for ADARx Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Rui Zhu · Executive Officer
  • Zhen Li · Executive Officer, Director
  • Carl Gordon · Director
  • Erez Chimovits · Director
  • Hongbo Lu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes amounts paid both in cash and pursuant to automatic conversion of indebtedness.”

Signed by Zhen Li, President & CEO. Source: SEC Form D, newest notice filed Aug 7, 2020. Read the notice at the SEC.

equitySEC
Jan 2020$5 MNo. 1$2 to $10 million

ADARx Pharmaceuticals, Inc.: Raise no. 1, Jan 2020

Investors in this round

3 investors had bought by the notice of Feb 6, 2020: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for ADARx Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Rui Zhu · Executive Officer
  • Zhen Li · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Zhen Li, President & CEO. Source: SEC Form D, newest notice filed Feb 6, 2020. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • ADARx Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2023).

    SEC Form D · Aug 2023

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Aug 2023

That is all the official record says: ADARx Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in ADARx Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
LAV Biosciences Fund V, L.P.Fund or asset managernot statednot statedHeld Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2026)SEC Form 3
LAV Fund VI, L.P.Fund or asset managernot statednot statedHeld Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2026)SEC Form 3
LAV Fund VI Opportunities, L.P.Fund or asset managernot statednot statedHeld Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2026)SEC Form 3
OrbiMed Advisors Israel II LtdFund or asset managernot statednot statedHeld Series A, B, B-1 and C preferred stock, 10% owner, director (Form 3, 2026)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series A, B, B-1 and C preferred stock, 10% owner, director (Form 3, 2026)SEC Form 3
OrbiMed Capital GP VII LLCFund or asset managernot statednot statedHeld Series A, B, B-1 and C preferred stock, 10% owner, director (Form 3, 2026)SEC Form 3
OrbiMed Israel GP II, L.P.Fund or asset managernot statednot statedHeld Series A, B, B-1 and C preferred stock, 10% owner, director (Form 3, 2026)SEC Form 3
SR One Capital Management, LLCFund or asset managernot statednot statedHeld Series B, B-1 and C preferred stock, 10% owner (Form 3, 2026)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 28 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by ADARx Pharmaceuticals, Inc.
NameRoleNamed in
Rui ZhuExecutive officerAug 2023
Zhen LiExecutive officerAug 2023
Carl GordonDirectorAug 2023
Chen YuDirectorAug 2023
Erez ChimovitsDirectorAug 2023
Judith LiDirectorAug 2023
Lorence KimDirectorAug 2023
Ricky SunDirectorAug 2023
Sheila GujrathiDirectorAug 2023
Simeon GeorgeDirectorAug 2023
Yuan (Eliza) SunDirectorAug 2023
Zhen LiDirectorAug 2023
Xiong ZhangDirectorAug 2021
Yuan SunDirectorAug 2021
Hongbo LuDirectorNov 2020
Zhen LiPromoterAug 2023